Vimarsana
Biggest News Aggregation in the World

Page 2 - William Gramig News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from William Gramig. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In William Gramig Today - Breaking & Trending Today

Cabaletta Bio : Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts - - Partnership for CABA-201 builds on existing manufacturing agreement for clinical trial supply of MuSK-CAART for MusCAARTes™ trial - Form 8-K -Today at 09:56 am - Vimarsana News

Cabaletta Bio : Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts - - Partnership for CABA-201 builds on existing manufacturing agreement for clinical trial supply of MuSK-CAART for MusCAARTes™ trial - Form 8-K -Today at 09:56 am

Published: August 22, 2023

- Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts...

Source: marketscreener.com
Related Topics:
United StatesGwendolyn BinderDavid Yh ChangWilliam GramigAnup MardaCabaletta Bio IncManufacturing OrganizationTechnology Of CabalettaExchange CommissionStern Investor Relations IncGood Manufacturing PracticeWuxi Advanced TherapiesContract TestingChief Technology OfficerWuxi ApptecCabaletta BioPrivate Securities Litigation Reform ActNature MedicineOrphan Drug DesignationFast TrackInvestor Relations
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 - Vimarsana News

Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201

Published: August 22, 2023

– Agreement expansion facilitates preparation for commercial readiness for CABA-201, enabling treatment of patients in multiple planned clinical trials with separate parallel cohorts – –...

Source: marketscreener.com
Related Topics:
United StatesGwendolyn BinderWilliam GramigDavid Yh ChangAnup MardaManufacturing OrganizationTechnology Of CabalettaCabaletta Bio IncStern Investor Relations IncExchange CommissionGood Manufacturing PracticeWuxi Advanced TherapiesContract TestingChief Technology OfficerWuxi ApptecCabaletta BioPrivate Securities Litigation Reform ActNature MedicineOrphan Drug DesignationFast Track DesignationInvestor Relations
Cabaletta Bio : Strengthened balance sheet by closing $100M public offering extending cash runway into the fourth quarter of 2025 - Vimarsana News

Cabaletta Bio : Strengthened balance sheet by closing $100M public offering extending cash runway into the fourth quarter of 2025

Published: August 10, 2023

- Strengthened balance sheet by closing $100M public offering extending cash runway into the fourth quarter of 2025 - PHILADELPHIA, Aug. 10,... -Today at 07:19 am- MarketScreener

Source: marketscreener.com
Related Topics:
New YorkUnited StatesAnup MardaSteven NichtbergerShawn TomaselloWilliam GramigStern Investor Relations IncAmerican Society Of GeneDrug AdministrationScience TechnologyCompany Board Of DirectorsGilead SciencesMorgan StanleyCabaletta Bio IncExchange CommissionChief Executive OfficerOperational HighlightsUpcoming AnticipatedInvestigational New DrugFast Track DesignationAnnual MeetingAmerican SocietyCell TherapyChief Commercial OfficerKite Pharma
Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update - Vimarsana News

Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Published: August 10, 2023

– Received second IND application clearance for CABA-201 in myositis as well as Fast Track Designation in SLE and LN – – Strengthened balance sheet by closing $100M public offering extending... -Today at 07:02 am- MarketScreener

Source: marketscreener.com
Related Topics:
New YorkUnited StatesAnup MardaSteven NichtbergerWilliam GramigShawn TomaselloExchange CommissionCabaletta Bio IncDrug AdministrationAmerican Society Of GeneMorgan StanleyScience TechnologyStern Investor Relations IncCompany Board Of DirectorsGilead SciencesFast Track DesignationChief Executive OfficerOperational HighlightsUpcoming AnticipatedInvestigational New DrugAnnual MeetingAmerican SocietyCell TherapyChief Commercial OfficerKite Pharma
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors - Vimarsana News

Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

Published: July 24, 2023

– Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 --...

Source: marketscreener.com
Related Topics:
United StatesShawn TomaselloAnup MardaWilliam GramigSteven NichtbergerMiles Pharmaceuticals IncKite Pharma IncAbbvie IncScience Technology CommitteeGilead Sciences IncProctor Gamble CompanyGenentech IncCompensation CommitteeExchange CommissionCelgene CorporationMurray State UniversityCabaletta Bio IncStern Investor Relations IncUniversity Of CincinnatiGilead SciencesKite PharmaChief Commercial OfficerChief Executive OfficerNational DirectorPfizer Laboratories